Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

The Lancet Infectious Diseases

Volumn 16, Issue 5, 2016, Pages 606-617

  Mallet, Vincent ^a,b,c   van Bömmel, Florian ^d   Doerig, Christopher ^e   Pischke, Sven ^f   Hermine, Olivier ^a   Locasciulli, Anna ^g   Cordonnier, Catherine ⁱ   Berg, Thomas ^d   Moradpour, Darius ^e   Wedemeyer, Heiner ^h   Ljungman, Per ^j  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g Cardiology Department   (Italy)

^h Hannover Centre for Internal Medicine   (Germany)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

CANCER CHEMOTHERAPY; DONOR; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; POSITIVE-STRAND RNA VIRUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS HEPATITIS; VIRUS REACTIVATION; ADVERSE EFFECTS; COMPLICATION; CONSENSUS DEVELOPMENT; HEMATOLOGIC NEOPLASMS; HEPATITIS, VIRAL, HUMAN;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS, VIRAL, HUMAN; HUMANS; LEUKEMIA; PRACTICE GUIDELINES AS TOPIC;

EID: 84963595179     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)00118-3     Document Type: Review

References (146)

1. Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012, 47:906-923. the European Group for Blood and Marrow Transplantation (EBMT).
2. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015, 50:1037-1056.
3. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015, 386:1546-1555.
4. Hope VD, Eramova I, Capurro D, Donoghoe MC Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014, 142:270-286.
5. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010, 28:3199-3202.
6. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
7. European Association for the Study of the Liver clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185. European Association for the Study of the Liver.
8. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015, 148:215-219.
9. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016, 63:261-283.
10. Cordonnier C, Calandra T The first European conference on infections in leukaemia: why and how?. Eur J Cancer 2007, 5:2-4.
11. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979, 121:1193-1254. The periodic health examination.
12. Kish MA Guide to development of practice guidelines. Clin Infect Dis 2001, 32:851-854.
13. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985, 151:599-603.
14. Chu CM, Liaw YF HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
15. Lai ME, Farci P, Figus A, Balestrieri A, Arnone M, Vyas GN Hepatitis B virus DNA in the serum of Sardinian blood donors negative for the hepatitis B surface antigen. Blood 1989, 73:17-19.
16. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
17. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990, 145:3442-3449.
18. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
19. Guidotti LG, Isogawa M, Chisari FV Host-virus interactions in hepatitis B virus infection. Curr Opin Immunol 2015, 36:61-66.
20. Wands JR Letter: Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 1975, 2:979.
21. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975, 2:528-530.
22. Perrillo RP Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
23. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988, 167:630-633.
24. Brugger SA, Oesterreicher C, Hofmann H, Kalhs P, Greinix HT, Müller C Hepatitis B virus clearance by transplantation of bone marrow from hepatitis B immunised donor. Lancet 1997, 349:996-997.
25. McIvor C, Morton J, Bryant A, Cooksley WG, Durrant S, Walker N Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 1994, 121:274-275.
26. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
27. Lok AS, McMahon BJ Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
28. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
29. Knöll A, Boehm S, Hahn J, Holler E, Jilg W Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat 2007, 14:478-483.
30. Ustun C, Koc H, Karayalcin S, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 20:289-296.
31. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011, 22:1170-1180.
32. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011, 31:403-404.
33. Mitka M FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013, 310:1664.
34. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991, 100:182-188.
35. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004, 11:141-147.
36. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002, 100:391-396.
37. Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011, 90:359-371. the BIOGEAS Study Group.
38. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003, 37:1320-1328. the Lymphoma Committee of Taiwan Cooperative Oncology Group.
39. Li X, Tian J, Wu J, et al. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study. Clin Ther 2009, 31:741-750.
40. Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review. Clin Rheumatol 2014, 33:577-586.
41. Laohapand C, Arromdee E, Tanwandee T Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int 2015, 9:202-208.
42. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:1049-1059.
43. Onozawa M, Hashino S, Izumiyama K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005, 79:616-619.
44. Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012, 91:1007-1012.
45. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013, 31:2765-2772.
46. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 2014, 32:3736-3743.
47. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002, 116:166-169.
48. Bae JH, Sohn JH, Lee HS, et al. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 2012, 18:225-228.
49. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91. the European Crohn's and Colitis Organisation (ECCO).
50. Tan J, Zhou J, Zhao P, Wei J Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012, 31:1169-1175.
51. Cantini F, Boccia S, Goletti D, et al. HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. Int J Rheumatol 2014, 2014:926836.
52. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005, 74:254-258.
53. Li J, Huang B, Li Y, Zheng D, Zhou Z, Liu J Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma 2015, 56:1710-1717.
54. Dervite I, Hober D, Morel P Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344:68-69.
55. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol 2013, 57:209-214.
56. Lu S, Xu Y, Mu Q, et al. The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy. Leuk Lymphoma 2015, 56:1027-1032.
57. Xu D, Fu J, Jin L, et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006, 177:739-747.
58. Mikulska M, Nicolini L, Signori A, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect 2014, 20:O694-O701.
59. Gwak GY, Koh KC, Kim HY Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007, 25:888-889.
60. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990, 49:708-713.
61. Reed EC, Myerson D, Corey L, Meyers JD Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. Blood 1991, 77:195-200.
62. Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010, 17:807-815.
63. Viganò M, Vener C, Lampertico P, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011, 46:125-131.
64. Yoo JJ, Cho EJ, Cho YY, et al. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. Liver Int 2015, 35:2530-2536.
65. Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant 2008, 14:1226-1230.
66. Chakvetadze C, Bani-Sadr F, Le Pendeven C, et al. Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis 2010, 50:1184-1186.
67. Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995, 86:3236-3240.
68. Lau GKK, Lie AKW, Kwong YL, et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000, 96:452-458.
69. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005, 42:813-819.
70. Hui CK, Lie A, Au WY, et al. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005, 5:1437-1445.
71. Shouval D, Ilan Y Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995, 23:98-101.
72. Lindemann M, Barsegian V, Runde V, et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation 2003, 75:833-838.
73. Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002, 122:614-624.
74. Marchou B, Excler JL, Bourderioux C, et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis 1995, 172:258-260.
75. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
76. Perrillo RP, Gish R, Falck-Ytter YT American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015, 148:221-244. e3.
77. Mahale P, Okhuysen PC, Torres HA Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?. Clin Gastroenterol Hepatol 2014, 12:1051-1054. e1.
78. Strasser SI, Myerson D, Spurgeon CL, et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999, 29:1893-1899.
79. Evans AT, Loeb KR, Shulman HM, et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. Am J Surg Pathol 2015, 39:212-220.
80. Fioredda F, Gigliotti AR, Haupt R, et al. HCV infection in very-long-term survivors after cancer chemotherapy and bone marrow transplantation: a single-center experience. J Pediatr Hematol Oncol 2005, 27:481-485.
81. Locasciulli A, Testa M, Valsecchi MG, et al. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study. Blood 1997, 90:3799-3805.
82. Paul IM, Sanders J, Ruggiero F, Andrews T, Ungar D, Eyster ME Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Blood 1999, 93:3672-3677.
83. Strickland DK, Riely CA, Patrick CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000, 95:3065-3070.
84. Ljungman P, Locasciulli A, de Soria VG, et al. Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy. Bone Marrow Transplant 2012, 47:1217-1221. the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
85. Peffault de Latour R, Lévy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004, 103:1618-1624.
86. Strasser SI, Sullivan KM, Myerson D, et al. Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999, 93:3259-3266.
87. Luppi M, Longo G, Ferrari MG, et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol 1998, 9:495-498.
88. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998, 83:1224-1230.
89. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006, 24:953-960. the Groupe d'Etude des Lymphomes de l'Adulte Programs.
90. Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012, 44:49-54.
91. Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol 2012, 57:1177-1185.
92. Watanabe T, Tanaka Y Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013, 43:113-121.
93. Barba P, Piñana JL, Fernández-Avilés F, et al. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients. Biol Blood Marrow Transplant 2011, 17:1653-1661.
94. Shuhart MC, Myerson D, Childs BH, et al. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 1994, 84:3229-3235.
95. Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation 1996, 62:1358-1360.
96. Beckerich F, Hézode C, Robin C, et al. New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. Blood 2014, 124:2613-2614.
97. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008, 6:451-458.
98. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003, 102:996-999.
99. Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996, 87:4296-4301.
100. Zuckerman E, Zuckerman T, Levine AM, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 1997, 127:423-428.
101. Pozzato G, Mazzaro C, Crovatto M, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994, 84:3047-3053.
102. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974, 57:775-788.
103. Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015, 62:234-237.
104. Sultanik P, Klotz C, Brault P, Pol S, Mallet V Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 2015, 125:2446-2447.
105. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005, 23:468-473.
106. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89-94.
107. Michot JM, Canioni D, Driss H, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 2015, 90:197-203. the ANRS HC-13 Lympho-C Study Group.
108. Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010, 116:5119-5125.
109. Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 2010, 85:46-50.
110. Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2014, 99:489-496.
111. La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. J Hepatol 2008, 49:557-563.
112. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012, 379:2477-2488.
113. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008, 358:811-817.
114. Baylis SA, Gärtner T, Nick S, Ovemyr J, Blümel J Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang 2012, 103:89-90.
115. Cleland A, Smith L, Crossan C, et al. Hepatitis E virus in Scottish blood donors. Vox Sang 2013, 105:283-289.
116. Corman VM, Drexler JF, Eckerle I, Roth WK, Drosten C, Eis-Hübinger AM Zoonotic hepatitis E virus strains in German blood donors. Vox Sang 2013, 104:179-180.
117. Gallian P, Lhomme S, Piquet Y, et al. Hepatitis E virus infections in blood donors, France. Emerg Infect Dis 2014, 20:1914-1917.
118. Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 2014, 384:1766-1773.
119. Ijaz S, Szypulska R, Tettmar KI, Kitchen A, Tedder RS Detection of hepatitis E virus RNA in plasma mini-pools from blood donors in England. Vox Sang 2012, 102:272.
120. Meldal BH, Sarkodie F, Owusu-Ofori S, Allain JP Hepatitis E virus infection in Ghanaian blood donors - the importance of immunoassay selection and confirmation. Vox Sang 2013, 104:30-36.
121. Slot E, Hogema BM, Riezebos-Brilman A, Kok TM, Molier M, Zaaijer HL Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill 2013, 18:20550.
122. Hogema BM, Molier M, Sjerps M, et al. Incidence and duration of hepatitis E virus infection in Dutch blood donors. Transfusion 2015, 56:722-728.
123. Andonov A, Rock G, Lin L, et al. Serological and molecular evidence of a plausible transmission of hepatitis E virus through pooled plasma. Vox Sang 2014, 107:213-219. the Members of the Canadian Apheresis Group (CAG).
124. Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014, 123:796-797.
125. Koenecke C, Pischke S, Beutel G, et al. Hepatitis E virus infection in a hematopoietic stem cell donor. Bone Marrow Transplant 2014, 49:159-160.
126. Versluis J, Pas SD, Agteresch HJ, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:1079-1086.
127. Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012, 55:695-708.
128. Mallet V, Le Mener S, Roque-Afonso AM, Tsatsaris V, Mamzer MF Chronic hepatitis E infection cured by pregnancy. J Clin Virol 2013, 58:745-747.
129. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011, 140:1481-1489.
130. Zhou X, Wang Y, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway. J Hepatol 2014, 61:746-754.
131. Wang Y, Zhou X, Debing Y, et al. Calcineurin inhibitors stimulate and mycophenolic acid inhibits replication of hepatitis E virus. Gastroenterology 2014, 146:1775-1783.
132. Mallet V, Nicand E, Sultanik P, et al. Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010, 153:85-89.
133. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 2013, 33:722-726.
134. Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014, 370:1111-1120.
135. Debing Y, Gisa A, Dallmeier K, et al. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 2014, 147:1008-1011. e7, quiz e15-16.
136. Shah JN, Chemaly RF Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011, 117:2755-2763.
137. Krumbholz A, Neubert A, Girschick H, et al. Prevalence of antibodies against hepatitis A virus among children and adolescents in Germany. Med Microbiol Immunol (Berl) 2013, 202:417-424.
138. Ghez D, Nicand E, Ferré V, et al. Allogenic bone marrow transplantation with a donor presenting with an acute hepatitis A. J Hepatol 2001, 34:625-630.
139. Koff RS, Hepatitis A Lancet 1998, 351:1643-1649.
140. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998, 338:286-290.
141. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118:255-267.
142. Rauff B, Idrees M, Shah SA, et al. Hepatitis associated aplastic anemia: a review. Virol J 2011, 8:87.
143. Chakvetadze C, Mallet V, Gaussec L, Hannoun L, Pol S Acute hepatitis A virus infection without IgM antibodies to hepatitis A virus. Ann Intern Med 2011, 154:507-508.
144. Hughes SA, Wedemeyer H, Harrison PM Hepatitis delta virus. Lancet 2011, 378:73-85.
145. Heidrich B, Yurdaydin C, Kabaçam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014, 60:87-97. the HIDIT-1 Study Group.
146. Hussain S, Jhaj R, Ahsan S, Ahsan M, Bloom RE, Jafri SM Bortezomib induced hepatitis B reactivation. Case Rep Med 2014, 2014:964082.